ImmuneOnco Published Preclinical Research data of IMM0306 in the Leukemia

A few days ago, the research team of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") published the research data of the product IMM0306 in the Leukemia. The peer-reviewed paper is in tittle of "IMM0306, a fusion pro......

2022-12-28

The phase II clinical study of ImmuneOnco’s IMM01 combined with azacitidine for first line treatment of high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) completed the enrollment of patients

On December 26, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced completion of patient enrollment for a phase II clinical trial. The study is IMM01, the first SIRPα-Fc fusion protein drug targeting hu......

2022-12-26

ImmuneOnco’s IMM2520 obtained approval of clinical research from the US FDA

On December 14, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the newly-developed bispecific antibody-receptor recombinant protein drug (project number: IMM2520), targeting CD47 and PD-L1, obt......

2022-12-14

Phase II clinical study of ImmuneOnco IMM01 combined with PD-1 monoclonal antibody against solid tumors and lymphomas officially launched

On December 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(hereinafter referred to as "ImmuneOnco") announced that phase II clinical studies of the first domestic SIRPαFc fusion protein targeting human CD47, IMM01，combined with PD-1 monoclonal ant......

2022-12-01

Phase II clinical trial application of ImmuneOnco: IMM0306 combined with lenalidomide for relapsed and refractory non-Hodgkin's lymphoma was accepted by NMPA

On November 18, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the independently developed bispecific antibody-receptor recombination targeting both CD47 and CD20, IMM0306, enters phase II clin......

2022-11-18